FDA Launches Pilot Program for One-Day Inspections

Food and Drug Administration

WASHINGTON, D.C. — The U.S. Food and Drug Administration is piloting one-day inspectional assessments across multiple regulatory programs as part of an effort to make agency oversight more targeted and efficient.

The pilot, launched in April, uses shorter screening assessments to supplement standard FDA inspections at selected facilities involved in human and animal foods, biologics, medical products and clinical research. The agency said facilities are chosen using risk-based criteria that include product type, inspection history and operational characteristics.

According to the FDA, the abbreviated assessments are designed to expand surveillance coverage while reducing operational disruptions for lower-risk facilities. Investigators retain authority to extend inspections beyond one day if significant compliance issues are identified.

READ:  FDA Expands Internal AI Tools With Elsa 4.0, HALO Platform

Marty Makary said the program is intended to improve how the agency allocates inspectional resources.

“One-day inspections can strengthen our inspectional approach by focusing our time and resources where they are most needed,” Makary said. “The ability to conduct shorter, targeted assessments allows for broader surveillance coverage, enabling the agency to assess more facilities and gather critical insights without compromising regulatory rigor.”

The FDA said information collected during the assessments could help develop more detailed risk models by identifying recurring compliance issues, facility-specific risk scores and inconsistencies between registered and actual operations.

READ:  FDA Authorizes Four Glas Vape Products With Age Controls

As of late April, the agency had completed about 46 one-day assessments. Most resulted in “No Action Indicated” findings, meaning inspectors found no significant violations or compliance concerns.

Elizabeth Miller said the agency is reviewing operational and compliance data from the pilot to determine how the approach could support broader inspection strategies.

The FDA said the pilot will continue through fiscal year 2026 and does not replace traditional inspections or alter existing enforcement policies. The agency added that higher-risk and more complex facilities will continue to receive comprehensive inspections.

Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.